文献速递乳腺MR

基于MRI结构栖息地影像的Ⅱ-Ⅲ期乳腺癌复发风险分层

Enhanced recurrence risk stratification for stages Ⅱ-Ⅲ breast cancer using MRI-based structure habitat imaging.
PubMed 文献 · Eur Radiol · 2026-09-19

这项多中心回顾性研究纳入842例Ⅱ-Ⅲ期乳腺癌女性,基于治疗前MRI无监督聚类识别肿瘤栖息地亚区并定义三种结构栖息地表型。表型在训练集和外部测试集中均显示不同无复发生存,且独立于肿瘤大小、淋巴结状态、临床亚型、病理分级和年龄。该表型可作为临床病理因素之外的复发风险分层辅助工具。

要点

  • 治疗前MRI可划分中央与外周两个结构亚区,形成三种栖息地表型
  • 三种表型无复发生存显著不同,测试集log-rank p<0.001
  • 表型在调整临床病理因素后仍为独立预后预测因子

核心结论

  • 治疗前MRI识别出两个结构栖息地亚区,衍生的SH表型在Ⅱ-Ⅲ期乳腺癌中提供超出临床病理因素的复发风险分层价值。

研究设计与样本

  • 多中心回顾性研究,纳入842例接受治疗前MRI及后续手术切除的Ⅱ-Ⅲ期乳腺癌女性,来自三个中心。
  • 多中心发现队列415例,外部测试队列427例。
  • 采用无监督聚类栖息地表征框架勾画肿瘤亚区并识别结构栖息地表型。
  • 以无复发生存为终点,采用Kaplan-Meier分析、多因素Cox回归及Fine-Gray竞争风险回归。

关键影像表现/征象

  • 在发现队列中识别出中央和外周两个具有独特影像组学模式的结构亚区。
  • 基于结构亚区识别出三种具有不同无复发生存的SH表型,并在测试队列中得到验证。

诊断标准与关键数值

  • 发现队列与测试队列中三种SH表型的无复发生存差异均有统计学意义,log-rank p<0.001。
  • 测试队列中SH表型2对比表型1的风险比为2.29,p=0.048。
  • 测试队列中SH表型3对比表型1的风险比为3.45,p=0.006。
  • 调整肿瘤大小、淋巴结受累、临床亚型、病理分级和患者年龄后,SH表型仍为独立预后预测因子。
  • 竞争风险回归分析得到相似结果。

临床应用与阅片要点

  • 该表型可作为经典临床病理因素的辅助手段,用于优化Ⅱ-Ⅲ期乳腺癌治疗计划中的复发风险分层。
  • 阅片时可关注治疗前MRI上肿瘤中央与外周亚区的结构差异,但文中未给出可直接目测的征象标准。

局限性

  • 本研究为回顾性设计。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

英文原文(摘要)· 点击展开

PURPOSE: To identify robust tumor habitat subregions using pre-treatment MRI and assess the prognostic value of the resulting phenotypes for recurrence risk stratification in stages II-III breast cancer.

METHODS: This multicenter retrospective study included 842 women with stages II-III breast cancer who received pre-treatment MRI scans and subsequent surgical resection from three centers (multicenter discovery cohort: n = 415; external test cohort: n = 427). An unsupervised clustering-based habitat characterization framework was applied to delineate tumor subregions and identify distinct structure habitat phenotypes (SH-phenotypes). Recurrence-free survival (RFS) was evaluated using Kaplan-Meier analysis and multivariate Cox regression. Fine-Gray competing risk regression was additionally used to account for death as a competing event.

RESULTS: Two structural subregions (central and peripheral) with unique radiomic patterns and three SH-phenotypes with distinct RFS were identified in the discovery cohort and validated in the test cohort (log-rank p < 0.001 for both). The SH-phenotypes remained independent prognostic predictors after adjustment for tumor size, nodal involvement, clinical subtype, pathological grade, and patient age [test cohort: SH-phenotype 2 vs 1, hazard ratio (HR) = 2.29, p = 0.048; SH-phenotype 3 vs 1, HR = 3.45, p = 0.006]. Similar results were obtained in the competing risk regression analysis.

CONCLUSIONS: Two structural habitat subregions were identified, and the derived SH-phenotypes provide additional prognostic value beyond clinicopathological factors for recurrence risk stratification in stages II-III breast cancer.

KEY POINTS: Question Precise evaluation of recurrence risk is crucial for tailoring therapy for stages II-III breast cancer, but it remains challenging with classical clinicopathological factors. Findings Pre-treatment MRI-based SH analysis identified three phenotypes with distinct RFS and recurrence cumulative incidence, independent of clinicopathological factors. Clinical relevance The clinical utility of this phenotyping lies in its role as an adjunct to classical clinicopathological factors, enhancing recurrence risk stratification for optimized treatment planning in stages II-III breast cancer.

来源:Eur Radiol,查看原文。版权归原作者所有。

引用

  1. Wang, Shi, Guo, et al. Enhanced recurrence risk stratification for stages Ⅱ-Ⅲ breast cancer using MRI-based structure habitat imaging. Eur Radiol. 2026. PMID: 42763333. doi:10.1007/s00330-026-12886-w

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。